Safety and Efficacy Study of MPC-4326 for Treatment of Patients With HIV-1 Infection.
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
To evaluate the antiretroviral activity and safety of 200 mg BID and 300 mg BID doses of
MPC-4326 administered as monotherapy for 14 days to HIV-1 positive patients. Patients with an
initial treatment response will have the option to continue MPC-4326 in combination with an
Optimized Backround Regimen for a maximum of 72 weeks.